TVTX240920P12500
- 0.45
- -0.05-10.00%
Travere Therapeutic Newsroom
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
Travere Therapeutics Price Target Raised to $23.00/Share From $18.00 by Canaccord Genuity
Travere Therapeutics Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $23
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Express News | Travere Therapeutics Inc : Guggenheim Raises to Buy From Neutral
Guggenheim Upgrades Travere Therapeutic(TVTX.US) to Buy Rating, Announces Target Price $25
There's No Escaping Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Muted Revenues Despite A 29% Share Price Rise
Travere (TVTX.US) receives full approval from the FDA for its "first-in-class" therapy, significantly slowing down the decline of kidney function.
On September 7, Travere Therapeutics (TVTX.US) announced that the U.S. FDA has fully approved the "first-in-class" therapy Filspari (sparsentan).
Analyst Ratings For Travere Therapeutics
Update: Wedbush Raises Travere Therapeutics PT to $19 From $16 After FDA's Approval of Filspari, Keeps Outperform Rating
Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (Sparsentan), the Only Non-Immunosuppressive Treatment That Significantly Slows Kidney Function Decline in IgA Nephropathy
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday
Express News | B of A Securities Maintains Buy on Travere Therapeutics, Raises Price Target to $19
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $10 to $23
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
Travere Therapeutics Says FDA Granted Full Approval of Kidney Drug Filspari; Shares Rise Pre-Bell
Travere Therapeutics Is Maintained at Buy by HC Wainwright & Co.